A61K 2039/577
Tolerising response
Official title: {tolerising response}
A61K2039/577 (Tolerising response) appears on 274 US grants and 675 published applications in this corpus.
Search patents in A61K- Granted patents
- 274
- Published applications
- 675
- Assignees
- 310
- Inventors
- 975
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 0 | 1 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 1 | 5 |
| 2011 | 0 | 5 |
| 2012 | 1 | 23 |
| 2013 | 3 | 23 |
| 2014 | 9 | 27 |
| 2015 | 8 | 51 |
| 2016 | 28 | 67 |
| 2017 | 28 | 61 |
| 2018 | 35 | 39 |
| 2019 | 21 | 47 |
| 2020 | 22 | 45 |
| 2021 | 23 | 42 |
| 2022 | 22 | 48 |
| 2023 | 15 | 53 |
| 2024 | 18 | 53 |
| 2025 | 19 | 43 |
| 2026 | 19 | 35 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Suppression of diabetes using exosomes from stem cell programmed myeloid cells22 Sep 2026US 12,741,015 B2Creative Medical Technologies, Inc.
- Modified antibodies15 Sep 2026US 12,734,208 B2Janux Therapeutics, Inc.
- Production of MHC II/CII complexes1 Sep 2026US 12,721,884 B2
- Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist18 Aug 2026US 12,708,666 B2Regeneron Pharmaceuticals, Inc.
- Composition and method for reducing allergic response11 Aug 2026US 12,702,642 B2Atg Acquisition LLC
- Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis8 Oct 2026US 2026/0306598 A1Cour Pharmaceuticals Development Company, Inc.
- Treatment of peanut allergy with tolerizing nanoparticles8 Oct 2026US 2026/0306622 A1Cour Pharmaceuticals Development Company, Inc.
- Tolerizing immune modifying nanoparticles for myasthenia gravis treatment24 Sep 2026US 2026/0284161 A1Cour Pharmaceuticals Development Company, Inc.
- Peptide conjugated particles24 Sep 2026US 2026/0284162 A1Northwestern University
- Therapeutic food products for food allergy treatment24 Sep 2026US 2026/0284182 A1
Most cited
By later US patents
- Tolerogenic synthetic nanocarriers for inducing regulatory B cells129US 8,652,487 B2Selecta Biosciences, Inc. · 2014
- Composition for inducing proliferation or accumulation of regulatory T cells98US 9,808,519 B2The University of Tokyo · 2017
- Composition for inducing proliferation or accumulation of regulatory T cells85US 9,662,381 B2The University of Tokyo · 2017
- Compositions comprising bacterial strains57US 9,987,311 B24D Pharma Research Limited · 2018
- Composition for inducing proliferation or accumulation of regulatory T cells53US 9,433,652 B2The University of Tokyo · 2016